Chongqing Medical Univ. FGFR4 compound 10f

Chongqing Medical Univ. FGFR4 compound 10f: sourced facts only. name: "The representative compound 10f displayed significant FGFR4 inhibition and reasonable selectivity." [PMID:39733483]; target: "The representative compound 10f displayed significant FGFR4 inhibition and reasonable selectivity." [PMID:39733483]; developer: "Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, PR China." [PMID:39733483]; modality: "a new class of Ponatinib-based N-phenylpyridine-2-amine derivatives was designed and synthesized as covalent and irreversible FGFR4 selective inhibitors" [PMID:39733483]; stage: "Meanwhile, compound 10f strongly suppressed the proliferation of FGFR4 dependent HCC cells both in vitro and in vivo by inhibiting the FGFR4 signaling pathway." [PMID:39733483]